| Document |
Document Title |
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/166994A1 |
Provided in the present invention are a naphthyl urea compound, a preparation method therefor and the use thereof. A naphthyl urea parent nucleus group with a biological activity contained in the naphthyl urea compound is further chemica...
|
|
WO/2022/160177A1 |
Disclosed is a method for preparing 6-hydroxy-6(hydroxymethyl)-2H-pyran-3(6H)-one by means of catalytic oxidation. The method comprises: using a titanium silicalite molecular sieve as a catalyst, hydrogen peroxide as an oxidant and water...
|
|
WO/2022/163209A1 |
A carbon dioxide absorber which comprises an amine compound (A) having a heterocyclic structure (X) selected from among oxygen-containing heterocyclic structures and sulfur-containing heterocyclic structures and which has a content of th...
|
|
WO/2022/151615A1 |
The present application relates to the field of pharmaceutical chemistry, and specifically relates to a synthesis method for a Tianagliflozin intermediate. The synthesis method for a Tianagliflozin intermediate comprises: preparing the T...
|
|
WO/2022/038365A9 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.
|
|
WO/2022/138670A1 |
Provided are a compound, polymer, composition, film-forming composition, pattern formation method, method for forming insulating films, and compound production method, that yield a resist that exhibits excellent exposure sensitivity. T...
|
|
WO/2022/126959A1 |
The present invention provides a nanoporous solid acid based on a silica aerogel and a preparation method therefor. In the nanoporous solid acid based on a silica aerogel of the present invention, the solid acid is dispersed in a nanopor...
|
|
WO/2022/127713A1 |
Disclosed is a device for continuous liquid alkane introduction in a Grignard reaction. The device comprises a liquid alkane storage tank and a Grignard reaction kettle, which are characterized in that: an outlet of the liquid alkane sto...
|
|
WO/2022/122028A1 |
Disclosed in the present application is a method for back-extraction purification of a crude product obtained by sublimation of maltol or ethyl maltol, comprising the following steps: step 1: heating the crude product obtained by sublima...
|
|
WO/2022/122027A1 |
Disclosed is a device for alcohol distillation decoloring and purification in maltol production. The device is characterized in comprising a rectifying column, an alkaline hydrolysis kettle and an alkaline hydrolysis rectifying column. A...
|
|
WO/2022/118321A1 |
The present invention relates to a process for the preparation of Eribulin.
|
|
WO/2022/116782A1 |
An ethyl maltol monoclonal antibody hybridoma cell line ABC01 and an application thereof in the analysis and detection of ethyl maltol residues in food safety testing. The hybridoma cell line was deposited in the China General Microbiolo...
|
|
WO/2022/112351A1 |
The present invention relates to malonamide compounds of the formula (I) wherein the variables are as defined in the claims and the description, and to compositions comprising these compounds. The invention also relates to the use of sai...
|
|
WO/2022/105845A1 |
A glucoside derivative, and a preparation method therefor and an application thereof. Specifically, provided is a glucoside derivative, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The ...
|
|
WO/2022/085379A1 |
Provided is a lactone compound that is represented by formula (1) and is useful as a flavor imparting agent. Also provided are a flavor imparting agent and a fragrance composition. In the formula, the dotted line in the heterocycle indic...
|
|
WO/2022/078487A1 |
The present disclosure provides a zolinose compound represented by formula (I), a preparation method therefor and a use thereof, wherein definitions of substituents are provided in the description. The zolinose compound has application p...
|
|
WO/2022/074631A1 |
The present invention provides a novel process for preparing and purifying SGLT2 inhibitor intermediate 2-chloro-5-iodobenzoic acid of formula II to 5 obtaina pharmaceutically accepted product of formula II with 56.25-59.5% yield and pur...
|
|
WO/2022/067724A1 |
Provided are an SGLT-2 inhibitor sarcosine co-crystal, a preparation method therefor and use thereof. Using sarcosine as a ligand, said co-crystal has higher safety and lower costs; a drug co-crystal has higher stability, and during the ...
|
|
WO/2022/062401A1 |
The present application belongs to the technical field of medicines, and specifically relates to a preparation method for tianagliflozin. The tianagliflozin of the present application is obtained by reacting a compound N-9, n-butyl lithi...
|
|
WO/2022/057522A1 |
A liquid crystal aligning agent, comprising at least one polymer selected from at least one of polyimide and a group of polyimide obtained by ring closure of said polyimide. The polyimide comprises a first dianhydride represented by form...
|
|
WO/2022/058965A1 |
Provided herein, inter alia, are compounds of fatty acid glycerol derivatives and compositions including the same.
|
|
WO/2022/053576A1 |
The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for examp...
|
|
WO/2022/013659A1 |
Disclosed is a new, alternative, low-cost synthesis method for producing carminic acid in vitro by means of haemolymph cells of the insect Dactylopius coccus Costa (cochineal), for use in the industry for colourants used for foods, cosme...
|
|
WO/2021/260617A1 |
The present invention relates to an improved process for preparation of Dapagliflozin propanediol monohydrate of formula (I). The invention further relates to an improved process for the preparation of substantially pure intermediate of ...
|
|
WO/2021/256181A1 |
The purpose of the present invention is to provide a method for producing, at a high yield, an aminoalkyl tetrahydropyran derivative for use in the treatment and/or prevention of pain. The present invention is a production method in whic...
|
|
WO/2021/255279A1 |
The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a compone...
|
|
WO/2021/253478A1 |
Disclosed is a photosensitive photoresist resin monomer containing a polycyclic β-ketone structure, which relates to the field of photoresist resin monomers. Structural formula (I) thereof is shown as follows: R1 is methyl or H, R2 and ...
|
|
WO/2021/248763A1 |
The present invention relates to a method for preparing laninamivir. A one-pot method is used to synthesize a laninamivir intermediate compound (5) from compound (4); and the reaction is mild and rapid, and the next reaction step may be ...
|
|
WO/2021/245533A1 |
Present invention relates to development of compound of formula (Ia) for treatment of inflammatory bowel diseases. Invention also relates to pharmaceutical composition comprising therapeutically effective compound of formula (Ia) for tre...
|
|
WO/2021/244638A1 |
Provided in the present invention are a Fenlean 7 position metabolite, and the preparation and the use thereof. The Fenlean 7 position metabolite of the present invention has a good antioxidant activity and anti-neuroinflammation and neu...
|
|
WO/2021/245253A1 |
A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more...
|
|
WO/2021/244635A1 |
Provided in the present invention are a metabolite at position 21 of Fenlean, and the preparation and the use thereof. The metabolite at position 21 of Fenlean of the present invention has a good antioxidant activity and anti-neuroinflam...
|
|
WO/2021/234449A1 |
New tetrahydrocannabinolic acid cocrystals are disclosed, in particular, a 1:1 tetrahydrocannabinolic acid L-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D-proline cocrystal, a 1:1 tetrahydrocannabinolic acid D, L-proline cocryst...
|
|
WO/2021/227441A1 |
A compound inhibiting a sodium-glucose cotransporter 1, and a pharmaceutically acceptable salt and a stereoisomer thereof. The compound is used in a pharmaceutical composition. Also disclosed are methods for preparing and using the pharm...
|
|
WO/2021/227439A1 |
Provided in the present invention are a compound for inhibiting sodium glucose cotransporter 1, and a pharmaceutically acceptable salt and a stereoisomer of the compound. The compound is used for a pharmaceutical composition, and further...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/213500A1 |
A compound of Formula (I) : (I) or a pharmaceutically acceptable salt thereof, in which Ring X is a 3 to 7 membered monocyclic ring, at least one of R1, R2, R3, and R4 is OR5 or CH2OR5 and the other R1, R2, R3, and R4 each independently ...
|
|
WO/2021/211765A1 |
A process for the production of dihydronepetalactone including hydrogenating nepetalactone in the presence of a catalytic metal is provided. The catalytic metal may include nickel. The process may be performed in an aqueous medium.
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/200179A1 |
The present invention provides an actinic-ray-sensitive or radiation-sensitive resin composition comprising (A) a resin which increases in polarity by the action of an acid and (B) a compound which generates an acid upon irradiation with...
|
|
WO/2021/200178A1 |
The present invention provides: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin in which polarity is increased due to acid activity, and (B) a compound which is represented by a specific general f...
|
|
WO/2021/201577A1 |
The present invention relates HMG-CoA reductase degradation inducing compounds. Specifically, the present invention relates a bifunctional compound in which a HMG-CoA reductase binding moiety and an E3 ubiquitin ligase-binding moiety are...
|
|
WO/2021/193786A1 |
The present invention provides: a 6-(fluoroalkyl)-3,4-dihydro-2H-pyran-5-carboxylic acid ester derivative represented by a specific formula (3); a method for producing the same; a method for producing a 2-(fluoroalkyl) nicotinic acid der...
|
|
WO/2021/187547A1 |
The present invention provides a useful compound and a mode suitable as a pharmaceutical agent ingredient thereof, as an agent for treating and/or preventing diseases caused by activation of a DP receptor, particularly as a therapeutic a...
|
|
WO/2021/184123A1 |
A method of treating a coronavirus infection involves administering an inhibitor of the Neu1 sialidase – G protein-coupled receptor - Matrix metalloproteinase 9 (Neu1-GPCR-MMP9) signaling platform, in particular administering intraveno...
|
|
WO/2021/179088A1 |
The present disclosure relates to a composition comprising: i) terpenes in a diamond construction for delivering a specific aroma profile; and ii) optionally, at least one cannabinoid. The present disclosure also relates to methods of us...
|
|
WO/2021/175971A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucosa.
|
|
WO/2021/170464A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R9 represent groups such as hydrogen, halogen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent ...
|
|
WO/2021/170913A1 |
Chemical modulators of PP2A, comprising tricyclic sulfonimidamides are disclosed. The compounds are useful in preventing or treating cancer, diabetes, autoimmune disease, solid organ transplant rejection, graft vs host disease, chronic o...
|
